Orthofix Medical Inc. is a medical device and biological products company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. The company is headquartered in Lewisville, Texas.
| Revenue (TTM) | $833.19M |
| Gross Profit (TTM) | $593.73M |
| EBITDA | $20.93M |
| Operating Margin | -3.26% |
| Return on Equity | -13.90% |
| Return on Assets | -2.74% |
| Revenue/Share (TTM) | $20.68 |
| Book Value | $10.54 |
| Price-to-Book | 0.85 |
| Price-to-Sales (TTM) | 0.38 |
| EV/Revenue | 0.593 |
| EV/EBITDA | 26.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $40.42M |
| Float | $40.41M |
| % Insiders | 2.17% |
| % Institutions | 96.13% |
Volatility is currently expanding
Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November 9, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing 833-461-5787 in the U.S., and 585-542-9983 in all other locations, and referencing th.
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.
Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment and profitable growth rather than pursuing revenue growth at any cost.
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OFIX and any ticker you trade — then tracks every position and per-strategy win rate.
